Caribou Biosciences, Inc. (CRBU)

Market Cap	79.27M
Revenue (ttm)	9.99M
Net Income (ttm)	-149.11M
Shares Out	93.00M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,194,973
Open	0.8152
Previous Close	0.7717
Day's Range	0.7510 - 0.8604
52-Week Range	0.6600 - 4.2100
Beta	2.36
Analysts	Strong Buy
Price Target	10.60 (+1,143.69%)
Earnings Date	May 9, 2025

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company’s lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: CRBU
• Website: https://cariboubio.com

Financial Performance

In 2024, Caribou Biosciences's revenue was $9.99 million, a decrease of -71.01% compared to the previous year's $34.48 million. Losses were -$149.11 million, 46.1% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price forecast is $10.6, which is an increase of 1,143.69% from the latest price.

Price Target

$10.6

(1,143.69% upside)

Analyst Consensus: Strong Buy